Social Media Buzz 5/14/12
Click on a company name to read relevant tweets and blog posts.
Arno Therapeutics has received orphan-drug designation for AR-42 to treat neurofibromatosis type 2 (NF2) in the Europe.
Cyclacel announces completion of enrollment in investigator-initiated, phase 2/3 randomized trial comparing sapacitabine to low dose cytarabine.
Ventus Medical to raise $40-million with an IPO and list on the ASX.